Ann: Sale of Investment in Omni Innovation, page-8

I think that the initial strategy was to use licensing agreements in order to generate revenue fairly quickly.

This failed to materialise in China with EHH. Due to the fact the EHH was listed in 2017 and we only have the Annual Report for 2018, it is not possible to determine the true impact of Hutang-1 on EHH's account but it seemed successful enough to warrant an upgrade in production line.

The next attempt at developing markets was through licencing agreement was with Myopharm on 14/01/2021 which as we know turned into a sales agreement.

Clearly the product is good otherwise Myopharm wouldn't jump on the opportunity to buyout Omni (at a very cheap price I must say).
The initial strategy to generate revenue was good and could have been successful but the execution was poor and COVID-19 defnitely didn't help a China centric strategy.